Ochre

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Retrieved on: 
Wednesday, May 17, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, University, Office for Strategic Coordination of Health Research, Doctor of Philosophy, Bio, Liver disease, CSO, Henley Business School, Hope, Physiology, MBA, Multimedia, Chairperson, Neurophysiology, MD, Patient, University of Pavia, Liver, Therapy, News, Pharmaceutical industry, Ochre, OSCHR

Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors.

Key Points: 
  • Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230516005212/en/
    Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors (Photo: Business Wire)
    The news follows the recent appointment of Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors, and David Coughlan, PhD as VP of Translational Development, as Ochre Bio continues to strengthen its leadership.
  • We are humbled to have him as part of the Ochre team.”
    Eliot Forster said, "I am honoured to join Ochre Bio as Chairperson.
  • He is also a Board member of OSCHR (Office for Strategic Coordination of Health Research), and the National Genomics Board.

Ochre Bio Announces Formation of Scientific Strategy Board with Liver Disease Experts

Retrieved on: 
Thursday, October 20, 2022
Technology, Research, Genetics, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Institute of Liver and Biliary Sciences, Bio, Koch Institute, PRO, Therapy, Liver disease, Koch Institute for Integrative Cancer Research, Science, University of Oxford, Strategic planning, Takeda, Patient, IMES, Biology, RNA, Tissue, Translational medicine, Division, Multimedia, Institute, Sanofi, GI, Technology, SVP, Extramural medical education in Edinburgh, Ragon Institute, Broad Institute, Industry, Obesity, Eric Schmidt, MIT, Faculty, Innovation, Associate, Ochre, CMO, Cirrhosis, Greater, Death, Chronic liver disease, SSB, Management, Pharmaceutical industry, Dietary supplement, Chemistry, Engineering, Novartis

Ochre Bio , an RNA therapeutics company focused on chronic liver and cardiometabolic diseases, announced today the formation of its scientific strategy board (SSB) to support the maturation of its platforms and pipeline of liver disease therapeutics.

Key Points: 
  • Ochre Bio , an RNA therapeutics company focused on chronic liver and cardiometabolic diseases, announced today the formation of its scientific strategy board (SSB) to support the maturation of its platforms and pipeline of liver disease therapeutics.
  • The SSB comprises leading experts across liver disease R&D, clinical development, and pharmaceutical partnering.
  • The company is developing a novel strategy that has potential to positively impact all patients with liver diseases.
  • Ochre is basically de-risking clinical trials, so more of the trials in liver disease will hopefully be successful.

Ochre Bio Raises $30M Series A Financing for the Development of RNA Therapies for Chronic Liver Diseases

Retrieved on: 
Monday, October 10, 2022
Software, Research, Other Health, Pharmaceutical, Data Management, Technology, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, Institute of Liver and Biliary Sciences, Bio, Transplant, Population, Patient, Drug development, RNA, Research, Multimedia, VC, Drug discovery, Obesity, EIT, CEO, Khosla Ventures, Death, Liver, Genomics, Ochre, Liver disease, Cirrhosis, Ageing, Chronic liver disease, Pharmaceutical industry, Dietary supplement, Medical imaging, Selvage

Ochre Bio , an innovator in chronic liver disease drug development, today announced the successful close of $30M in Series A financing.

Key Points: 
  • Ochre Bio , an innovator in chronic liver disease drug development, today announced the successful close of $30M in Series A financing.
  • View the full release here: https://www.businesswire.com/news/home/20221010005172/en/
    Ochre Bio Co-Founders Quin Wills, Ph.D., Chief Scientific Officer (left) and Jack O'Meara, Chief Executive Officer (right).
  • The findings from this human liver pre-clinical testing over 2023 will inform which therapies they move into clinical development in 2024.
  • Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases.

Ochre Bio Launches ‘Liver ICU’ in the United States to Evaluate Effects of RNA Therapies on Human Liver Performance

Retrieved on: 
Wednesday, May 11, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Laboratory, Ochre, CSO, Bio, Transplant, Chronic liver disease, RNA, Liver disease, Yale University, Institute of Liver and Biliary Sciences, Doctor of Philosophy, Patient, Partnership, Organization, Cirrhosis, FDA, Therapy, Genomics, Yale School of Medicine, Science, Physiology, Model for End-Stage Liver Disease, LifeSharers, Organ transplantation, Assistant, Liver transplantation, CEO, New England Biolabs, Research, Dietary supplement, Medical imaging, Dentistry

Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their Liver ICU.

Key Points: 
  • Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their Liver ICU.
  • Housed in BioLabs@NYULangone, a biopharma incubator in New York City, this research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.
  • This site is a part of a network of three leading liver perfusion research sites across the US.
  • Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases.

Speck Design and Innovator Kyla Wilkenson Create a Truly Wireless Magsafe "Puck" Charger

Retrieved on: 
Wednesday, April 6, 2022
IG, Human, Science, Tesla, Electricity, SAN, Dares Phrygius, Marketing, Mobile phone, Ochre

The idea, like the execution, is artfully simple. A charging station that plugs into the wall with a detachable "puck" that magnetically attaches to the back of a phone case or phone. And guess what? That puck charges phones-- sans wire--for reals. This means gone are the days of pacing around tethered to the wall--"wirelessly charging" a phone--when all that is needed are a few bars to get through.

Key Points: 
  • SAN JOSE, Calif., April 6, 2022 /PRNewswire-PRWeb/ --Most individuals have probably heard about a little something called wireless charging.
  • In theory, it has been a "thing" since Nikola Tesla attempted to create a wireless power transmission by pumping out giant fields of electricity between two massive towers.
  • Fundamentally the science behind wireless cellphone chargers hasn't changed much throughout the years, and surprisingly--neither have the product's features and design aesthetics.
  • Kyla saw it, too--then decided to do something about it and started working with Speck Design (speckdesign.com), the product design house behind the Pop Socket.

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

Retrieved on: 
Tuesday, December 14, 2021
Philanthropy, Health, Foundation, Research, Science, Pharmaceutical, Biotechnology, RNA, HMRC, Genomics, Revenue, Awareness, Bio, Liver disease, Cancer, Risk, The British Liver Trust, Caregiver, Chronic liver disease, Liver, CEO, Research, Goal, Patient, Therapy, Charity Commission for England and Wales, Â, Best practice, Ochre, Partnership, Heart, Pharmaceutical industry, Dietary supplement

Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, announced today to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health.

Key Points: 
  • Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, announced today to have entered into a Charitable Donation Agreement with the British Liver Trust in support of improving awareness for liver health.
  • As we are progressing our preclinical evaluation, we are proud to support the great work of the British Liver Trust.
  • The British Liver Trust is the UK's leading liver health charity, recognised by Her Majesty's Revenue and Customs (HMRC) and the Charity Commissions in England, Wales and Scotland, is working to improve liver health and supporting patients affected by liver disease or cancer.
  • We are really excited that Ochre Bio is supporting the aims of the British Liver Trust and we delighted to have this partnership with important shared goals, added Pamela Healy OBE, Chief Executive of the British Liver Trust
    Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer.

Ochre Bio Closes $9.6M Seed Financing Led by Khosla Ventures

Retrieved on: 
Wednesday, June 16, 2021
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, Feminine given names, Financial markets, Given names, Agencies of the European Union, European Union, European Securities and Markets Authority, Systemic risk, Esma, European Market Infrastructure Regulation, Ochre, Liver

Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, today announced the closing of a $9.6M seed financing round led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek.

Key Points: 
  • Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, today announced the closing of a $9.6M seed financing round led by Khosla Ventures, with participation from Backed VC, Apollo Health Ventures, Selvedge, Hoxton and Hermes-Epitek.
  • In addition to deep phenotyping of human livers, Ochre Bio is able to test therapeutics in explanted livers being maintained extracorporeally.
  • This financing will allow us to advance development of our therapeutic platform, as well as move products toward clinical development, said Jack OMeara, CEO & Co-Founder, Ochre Bio.
  • Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer.

Canterra Minerals Identifies a New Gold Target and Expands the Red Ochre Complex through Soil Sample Results at the Wilding Gold Project, Newfoundland

Retrieved on: 
Wednesday, May 5, 2021
Iron ores, Electromagnetism, Minerals, Chemical compounds, Ochre, Magnetism, Magnetite, Magnetic susceptibility

The soils had been collected as infill sampling of previous widely spaced soil sampling to the south and northeast of the Red Ochre.

Key Points: 
  • The soils had been collected as infill sampling of previous widely spaced soil sampling to the south and northeast of the Red Ochre.
  • Other samples had been collected to the north and northeast and were part of the regional soil program.
  • Airborne magnetic data reveals that the magnetic porphyry forms long linear belts that extend to both the northeast and to the southwest of Red Ochre.
  • Magnetic susceptibility measurements of diamond drill core from Red Ochre reveal that gold is associated with zones of intense magnetite destruction within the porphyry.

Canterra Minerals Starts Drilling at the Wilding Gold Project, Newfoundland

Retrieved on: 
Wednesday, February 24, 2021
Ochre

Drilling will target expansion of known gold mineralization in several zones, including Red Ochre, Elm, and Alder

Key Points: 
  • Drilling will target expansion of known gold mineralization in several zones, including Red Ochre, Elm, and Alder
    Red Ochre Complex Historical Drilling Highlights:
    Red Ochre contains the widest intercepts of disseminated gold mineralization at Wilding, with gold mineralization hosted in quartz veins within altered and pyritic feldspar porphyry.
  • We are excited to have the drill now turning on Canterras maiden drill program at the Wilding Gold Project.
  • About the Wilding Gold Project:
    The Wilding Gold Project is located in Central Newfoundland, 50km south of Millertown, and directly northeast of Marathon Golds Valentine Lake Gold Project.
  • A $2.75 million exploration program is underway, focusing on drilling and surface exploration on the Wilding Gold Project.